Elicio Therapeutics Inc
ELTX
Company Profile
Business description
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Contact
451 D Street
5th Floor
BostonMA02210
USAT: +1 857 209-0050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
26
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.40 | 25.00 | -0.28% |
| CAC 40 | 7,850.43 | 106.02 | 1.37% |
| DAX 40 | 24,240.82 | 198.92 | 0.83% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,061.49 | 37.68 | 0.42% |
| HKSE | 25,688.87 | 150.80 | 0.59% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,866.16 | 694.84 | 1.69% |
| NZX 50 Index | 12,808.84 | 14.78 | 0.12% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,707.10 | 30.10 | -0.34% |
| SSE Composite Index | 3,599.44 | 17.14 | 0.48% |